Details of the Drug Combination

General Information of Drug Combination (ID: DCQS7O6)

Drug Combination Name
Eribulin AL3818
Indication
Disease Entry Status REF
HER2-negative Breast Cancer Phase 2 [1]
Component Drugs Eribulin   DM1DX4Q AL3818   DM3WP0N
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Eribulin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Liposarcoma 2B59 Approved [3]
Eribulin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------
Eribulin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of AL3818
Disease Entry ICD 11 Status REF
Alveolar soft part sarcoma 2A60-2C35 Phase 3 [4]
Leiomyosarcoma 2B58 Phase 3 [4]
Synovial sarcoma 2B5A Phase 3 [4]
Cervical cancer 2C77.0 Phase 1/2 [4]
Endometrial cancer 2C76 Phase 1/2 [4]
Fallopian tube cancer 2C74 Phase 1/2 [4]
Ovarian cancer 2C73 Phase 1/2 [4]
Peritoneal cavity cancer 2C51.Z Phase 1/2 [4]
AL3818 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
AL3818 Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04624711) Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
3 Eribulin FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
7 Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.